This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
3-5 November 2026
RAIAmsterdam, Netherlands
Menu

Tsubasa Aoki, PhD
Researcher at Ajinomoto Co., Inc.
Speaker

Profile

Dr. Tsubasa Aoki has been dedicated to antibody engineering, aiming to develop novel drug modalities as a researcher at Ajinomoto Co., Inc. His work includes the development of antibody-oligonucleotide conjugates and antibody-protein conjugates by using our proprietary conjugation technology, AJICAP®. Dr. Aoki earned his Ph.D. in Engineering from the University of Tokyo, Japan, in 2023. His doctoral research focused on chiroptical properties of the self-assembly systems.

Agenda Sessions

  • Accelerating the Development of Antibody-Oligonucleotide Conjugates (AOCs) by AJICAP® Site-Specific Chemical Conjugation Technology

    , 13:25
    View Session

At this event

Prev
Next
Mimoun Ayoub, PhD
Senior VP, Global Head of Peptide and Oligonucleotide Platforms
CordenPharma International

See Tsubasa at TIDES Europe: Oligonucleotide and Peptide Therapeutics